Curasen
9 known investors
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling. It targets psychiatric and neurodegenerative conditions including Parkinson's disease, Alzheimer's disease, neurogenic orthostatic hypotension, PSP, and ALS.
Founders & leadership
AF
Anthony Fordin
Investors · 9
Alta Partners✓ verifiedJackson · $1M – $12M
Longitude Capital✓ verifiedMenlo Park · $10M – $30M
abrdn plc✓ verifiedEdinburgh
Intermediate Capital Group✓ verifiedLondon · $5M – $50M
Johnson & Johnson Innovation – JJDC✓ verifiedNew Brunswick
New Leaf Venture Partners✓ verifiedNew York
Pappas Capital✓ verifiedResearch Triangle Park · $100K – $6M
Chiesi VenturesBoston · $5M
Pappas CapitalDurham
In the news
Frequently asked questions
- What does Curasen do?
- CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling. It targets psychiatric and neurodegenerative conditions including Parkinson's disease, Alzheimer's disease, neurogenic orthostatic hypotension, PSP, and ALS.
- Who are Curasen's investors?
- Curasen's investors include Alta Partners, Longitude Capital, abrdn plc, Intermediate Capital Group, Johnson & Johnson Innovation – JJDC, New Leaf Venture Partners, Pappas Capital, Chiesi Ventures and 1 more.